Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05607004 · ClinicalTrials.gov registry record · Phase 2
(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer
A Phase 2 study of Breast Neoplasms and HER2-Negative Breast Cancer, sponsored by Atossa Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 87
- Enrollment target
- 15
- Study locations
NCT05607004 is a Phase 2 study of Breast Neoplasms and HER2-Negative Breast Cancer that is actively recruiting participants, run by Atossa Therapeutics. The registered enrollment target is 87 participants, below the 568-participant average among 97 other Breast Neoplasms trials with a reported enrollment target (85% lower). The trial reports 15 study locations across 13 states.
The verdict
NCT05607004, a Phase 2 study of Breast Neoplasms and HER2-Negative Breast Cancer, is actively recruiting participants, sponsored by Atossa Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 87 participants
- Enrollment target
- 15
- Study locations
Study Summary
This open-label research study is studying (Z)-endoxifen as a possible treatment for pre-menopausal women with ER+/HER2- breast cancer. (Z)-endoxifen belongs to a group of drugs called selective estrogen receptor modulators or "SERM", which help block estrogen from attaching to cancer cells. This study has two parts: a pharmacokinetic part and a treatment part. The PK part (how the body processes the drug) will enroll about 18 participants. All participants will take (Z)-endoxifen capsules daily. Twelve participants will be randomly assigned (50/50 chance) to take (Z)-endoxifen alone or (Z)-endoxifen with a monthly injection of goserelin a drug that temporarily stops the ovaries from making estrogen. This part will help determine the best dose of (Z)-endoxifen by measuring the drug levels in the blood and how long the body takes to remove it. The Treatment Cohort has been simplified to a single study arm (Z)-endoxifen + goserelin. Up to 20 participants will be enrolled that have a baseline Ki-67 ≤ 10% and 45 participants will be enrolled that have a baseline Ki-67\>10%. A key goal of the study is to see if (Z)-endoxifen can slow down or stop tumor growth as measured by a reduction in Ki-67 levels. Tumor tissue samples will be taken by breast biopsy after about 4 weeks of treatment to check levels of this biomarker. If the tumor shows signs of response, participants can continue treatment for up to 24 weeks or until they have surgery. Study participation is up to 6 months (24 weeks of treatment) followed by surgery and a one-month follow up visit.
Conditions Studied
Interventions
- DRUG (Z)-endoxifen
- DRUG goserelin
Study Locations (15)
Arizona
- Mayo Clinic Arizona - Phoenix
- University of Arizona - Tucson
Texas
- Baylor University - Houston
- Tranquility Research - Webster
California
- California Research Institute - Los Angeles
Florida
- Mayo Clinic Florida - Jacksonville
Illinois
- Northwestern University - Chicago
Kentucky
- St. Elizabeth Healthcare - Edgewood
Michigan
- Henry Ford Cancer Institute - Detroit
Minnesota
- Mayo Clinic Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 87 participants |
| Start Date | 2023-02-14 |
| Est. Completion | 2027-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05607004
The ClinicalTrials.gov registry entry for NCT05607004 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 87 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 568-participant average among 97 other Breast Neoplasms trials with a reported enrollment target (85% lower). The listed sponsor is Atossa Therapeutics, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Breast Neoplasms appearing as the primary indexed condition, and to 2 interventions - of which (Z)-endoxifen is the first listed.
NCT05607004 reports 15 study locations spanning 13 distinct geographic areas - top geographies include Arizona, Texas, California.
Frequently Asked Questions
What is clinical trial NCT05607004 about?
NCT05607004 is a clinical study titled "(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer". This open-label research study is studying (Z)-endoxifen as a possible treatment for pre-menopausal women with ER+/HER2- breast cancer. (Z)-endoxifen belongs to a group of drugs called selective estrogen receptor modulators or "SERM", which help block estrogen from attaching to cancer cells. This st...
What is the current status of trial NCT05607004?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 87 participants. The study started on 2023-02-14. Estimated completion is 2027-04.
What conditions does trial NCT05607004 study?
This clinical trial studies the following conditions: Breast Neoplasms, HER2-Negative Breast Cancer, Invasive Breast Cancer, Estrogen Receptor-positive Breast Cancer.
What interventions are being tested in trial NCT05607004?
The interventions under investigation include: (Z)-endoxifen (DRUG), goserelin (DRUG).
Who is sponsoring clinical trial NCT05607004?
This trial is sponsored by Atossa Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05607004 being conducted?
This trial has 15 study locations across Arizona, California, Florida, Illinois, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
RECRUITING · Phase 2
-
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
RECRUITING · Phase 2
-
Tirzepatide Weight Loss for MRD+ Early Breast Cancer
RECRUITING · Phase 2
-
PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)
RECRUITING · Phase 2
-
Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
RECRUITING · Phase 2
-
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.